retatrutide parkinson clinical trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a parkinson's disease retatrutide clinical trial

2025;48(3):e25-e27

Future studies specifically designed to evaluate hormonal contributions (e.g., estrogenGLP-1 receptor interactions) will be important to mechanistically clarify these sex differences

Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism

The ability of Semaglutide GLP-1, Mounjaro, Wegovy, and Ozempic to maintain long-term weight loss varies due to a number of individual circumstances

[DOI] [PMC free article] [PubMed] [Google Scholar] 86.Kaur C, Ling EA

MEDVi highlights that 93% of its patients keep the weight off after initial loss, provided they remain consistent with treatment and follow the care plan